← All trials
NCT04606537
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Oct 24, 2020
- Primary completion
- Dec 1, 2020
- Completion date
- Dec 1, 2020
- First posted
- Oct 28, 2020
- Last posted
- Nov 10, 2020
- Enrollment
- 24
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- KBP BiosciencesLead sponsor
- CovanceCollaborator
- KBP BiosciencesStudy director
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.